ORKA
Income statement / Annual
Last year (2024), Oruka Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Oruka Therapeutics, Inc.'s net income was -$83.72 M.
See Oruka Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$27.00 K
|
$111.00 K
|
$114.00 K
|
$91.00 K
|
$93.00 K
|
$89.00 K
|
$22.00 K
|
$27.00 K
|
$24.00 K
|
$19.00 K
|
| Gross Profit |
-$27.00 K
|
-$111.00 K
|
-$114.00 K
|
-$91.00 K
|
-$93.00 K
|
-$89.00 K
|
-$22.00 K
|
-$27.00 K
|
-$24.00 K
|
-$19.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$75.06 M
|
$1.01 M
|
$4.46 M
|
$13.83 M
|
$4.99 M
|
$1.83 M
|
$4.24 M
|
$14.08 M
|
$12.35 M
|
$7.06 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.04 M
|
$6.17 M
|
$5.26 M
|
$5.41 M
|
$4.68 M
|
$3.89 M
|
$3.86 M
|
$4.61 M
|
$4.24 M
|
$4.37 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$88.10 M
|
$7.19 M
|
$9.73 M
|
$19.24 M
|
$9.67 M
|
$5.73 M
|
$8.10 M
|
$18.69 M
|
$16.59 M
|
$11.44 M
|
| Cost And Expenses |
$88.12 M
|
$7.30 M
|
$9.84 M
|
$19.34 M
|
$9.77 M
|
$5.81 M
|
$8.12 M
|
$18.71 M
|
$16.61 M
|
$11.46 M
|
| Interest Income |
$5.86 M
|
$1.96 M
|
$675.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$169.00 K
|
$14.00 K
|
| Interest Expense |
$1.47 M
|
$0.00
|
$0.00
|
$0.00
|
$9.00 K
|
$7.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$27.00 K
|
$111.00 K
|
$114.00 K
|
$91.00 K
|
$93.00 K
|
$89.00 K
|
$22.00 K
|
$27.00 K
|
$24.00 K
|
$19.00 K
|
| EBITDA |
-$82.23 M |
-$5.23 M |
-$9.81 M |
-$19.23 M |
-$9.65 M |
-$5.55 M |
-$7.94 M |
-$18.52 M |
-$16.42 M |
-$11.43 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.40 M
|
$1.96 M
|
-$85.00 K
|
$13.00 K
|
$19.00 K
|
$165.00 K
|
$154.00 K
|
$161.00 K
|
$169.00 K
|
$10.00 K
|
| Income Before Tax |
-$83.72 M
|
-$5.34 M
|
-$9.93 M
|
-$19.32 M
|
-$9.75 M
|
-$5.65 M
|
-$7.96 M
|
-$18.55 M
|
-$16.44 M
|
-$11.45 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$9.00 K
|
-$167.00 K
|
-$31.00 K
|
-$61.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$83.72 M
|
-$5.34 M
|
-$9.93 M
|
-$19.32 M
|
-$9.74 M
|
-$5.48 M
|
-$7.93 M
|
-$18.49 M
|
-$16.44 M
|
-$11.45 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.99 |
-4.44 |
-8.27 |
-16.68 |
-8.4 |
-49.79 |
-123.73 |
-382.87 |
-390.96 |
-393.12 |
| EPS Diluted |
-4.99 |
-4.44 |
-8.27 |
-16.68 |
-8.4 |
-49.79 |
-123.73 |
-382.87 |
-390.96 |
-393.12 |
| Weighted Average Shares Out |
$16.79 M
|
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$110.10 K
|
$64.12 K
|
$48.29 K
|
$41.98 K
|
$29.12 K
|
| Weighted Average Shares Out Diluted |
$16.79 M
|
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$110.10 K
|
$64.12 K
|
$48.29 K
|
$41.98 K
|
$29.12 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
